Immunovia presents data from discovery study at 2024 PancreasFest medical conference
LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company’s next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting (abstract #P33). PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the Collaborative Alliance for Pancreatic Education and